Lisa Richters

发表

A Retrospective Analysis of Ki-67 Index and its Prognostic Significance in Over 800 Primary Breast Cancer Cases.

S. Hamacher, P. Mallmann, F. Thangarajah, 2017, Anticancer research.

BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer

J. Ramser, A. Meindl, R. Schmutzler, 2018, Breast Cancer Research.

Ovarian Cancer–Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial

D. Dietrich, L. Wessels, P. Nederlof, 2021, Clinical Cancer Research.

Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial

H. Horlings, P. V. van Dam, P. Nederlof, 2022, International journal of cancer.

Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883)

A. Reuss, H. Gevensleben, D. Dietrich, 2019, Journal of Medical Genetics.

Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in BRCA1/2: results of the observational AGO-TR1 study (NCT02222883)

A. Reuss, H. Gevensleben, D. Dietrich, 2020, Journal of Medical Genetics.

Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility

J. Benítez, Å. Borg, R. Schmutzler, 2017, Genetics in Medicine.

ESR1-promoter-methylation status in primary breast cancer and its corresponding metastases

M. Odenthal, J. Fries, F. Thangarajah, 2018, Clinical & Experimental Metastasis.

Intraoperative Boost Radiotherapy during Targeted Oncoplastic Breast Surgery: Overview and Single Center Experiences

R. Semrau, C. Fridrich, P. Mallmann, 2014, International journal of breast cancer.

Review Article Intraoperative Boost Radiotherapy during Targeted Oncoplastic Breast Surgery: Overview and Single Center Experiences 1. Breast Surgery in an Oncoplastic Approach

R. Semrau, C. Fridrich, P. Mallmann, 2022 .

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)

A. Reuss, H. Gevensleben, D. Dietrich, 2017, PloS one.

Cervical screening program and the psychological impact of an abnormal Pap smear: a self-assessment questionnaire study of 590 patients

Katja Engel, P. Mallmann, F. Thangarajah, 2016, Archives of Gynecology and Obstetrics.

A randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine versus capecitabine monotherapy in first-line HER2-negative metastatic breast cancer (MBC).

N. Harbeck, L. Goldstein, B. Schmalfeldt, 2013 .

The Oncological Emergency Case: Paraneoplastic Hypoglycemia in Metastatic Breast Cancer - Case Report and Brief Review of the Literature

N. Harbeck, M. Ortmann, K. Rhiem, 2013, Breast Care.

Clinical implications of incorporating genetic and non-genetic risk factors in CanRisk-based breast cancer risk prediction.

P. Devilee, C. V. van Asperen, B. Wappenschmidt, 2023, Breast.

Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer

A. Meindl, R. Schmutzler, Jan Hauke, 2019, Breast Cancer Research.